Glaukos Corporation, a private ophthalmic company based in California, has announced the FDA approval of their glaucoma implant device, marketed as the “iStent Trabecular Micro-Bypass”. The device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication, according to a company press release. Referenced by the company as “the smallest medical device to be implanted into the human body”, the 1mm implant, constructed of non-ferromagnetic titanium, is implanted in conjunction with cataract surgery via insertion into Schlemm’s canal using an inserter and intra-operative gonioscopy.
US FDA approve new glaucoma implant device sponsored by Glaukos
- by swdadmin